Jeffrey H. Shuhaiber
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jeffrey H. Shuhaiber has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Jong Bae Kim
3 shared publications- Kimberley Goldsmith
King’s College London
3 shared publications Kwan Hur
Center for Health Statistics, University of Illinois at Chicago, Chicago, Illinois
3 shared publicationsRobert D. Gibbons
3 shared publicationsHassan Nemeh
2 shared publicationsMamdouh Bakhos
The Cardiovascular Institute, Loyola University Medical Center, Stritch School of Medicine, Maywood, Illinois
2 shared publications
Latest Publications
- 9 November 2011
- Published by Springer Nature in Cardiovascular Engineering and Technology
- Vol. 3 (1) , 112-122
The Diagnostic Efficacy of Left Ventricle Hemodynamic Parameters: Classifying Normal Mitral Valves Against Prosthetic Disease Proxies
- 9 November 2011
- Published by Springer Nature in Cardiovascular Engineering and Technology
- Vol. 3 (1) , 112-122
The Diagnostic Efficacy of Left Ventricle Hemodynamic Parameters: Classifying Normal Mitral Valves Against Prosthetic Disease Proxies
- 1 May 2009
- Published by Hindawi Limited in Journal of Cardiac Surgery
- Vol. 24 (3) , 250-255
Does the Type of Ventricular Assisted Device Influence Survival, Infection, and Rejection Rates Following Heart Transplantation?
To determine the influence of the type of left ventricular assisted device (LVAD) as predictor of survival, hospitalizations due to infection, and rejection following heart transplantation and to delineate any further predictors of such outcomes. Patients who received a left ventricular assist device (HeartMate [Thoratec Corp., Pleasanton, CA, USA] or Novacor [World Heart Corporation, Ottawa, Canada]) as a bridge to heart transplantation between October 1991 and June 2004 using the United Network for Organ Sharing (UNOS) Thoracic Registry database were evaluated. Comparison of survival curves between HeartMate and Novacor was performed using Kaplan-Meier survival method and Cox proportional hazard model adjusting for patient demographics and co-morbidities. Infection and rejection rates between the two devices were analyzed using multivariable logistic regression model. The UNOS database provided 1255 patients with HeartMate and 154 patients with Novacor between 1991 and 2004. Unadjusted one- and five-year survivals for HeartMate and Novacor were 0.84 and 0.80 and 0.72 and 0.56, respectively, following heart transplantation. Adjusting for patient demographics and co-morbidities, no statistical significant difference in one-year survival was observed between those who received HeartMate and Novacor (HR = 1.49, p = 0.127). At five years, however, the HeartMate group had higher survival than Novacor (HR = 1.53, p = 0.043). All-time posttransplant hospitalizations due to infection and rejection were similar between HeartMate and Novacor recipients after adjusting for patient case mix. Controlling for patient case mix, there was no survival difference at one year between those who received Novacor versus HeartMate LVAD. At five years, a Novacor bridge to transplant patient on average had statistically significantly lower survival than HeartMate recipients. No difference in infection and rejection were observed.
- 1 May 2009
- Published by Hindawi Limited in Journal of Cardiac Surgery
- Vol. 24 (3) , 250-255
Does the Type of Ventricular Assisted Device Influence Survival, Infection, and Rejection Rates Following Heart Transplantation?
To determine the influence of the type of left ventricular assisted device (LVAD) as predictor of survival, hospitalizations due to infection, and rejection following heart transplantation and to delineate any further predictors of such outcomes. Patients who received a left ventricular assist device (HeartMate [Thoratec Corp., Pleasanton, CA, USA] or Novacor [World Heart Corporation, Ottawa, Canada]) as a bridge to heart transplantation between October 1991 and June 2004 using the United Network for Organ Sharing (UNOS) Thoracic Registry database were evaluated. Comparison of survival curves between HeartMate and Novacor was performed using Kaplan-Meier survival method and Cox proportional hazard model adjusting for patient demographics and co-morbidities. Infection and rejection rates between the two devices were analyzed using multivariable logistic regression model. The UNOS database provided 1255 patients with HeartMate and 154 patients with Novacor between 1991 and 2004. Unadjusted one- and five-year survivals for HeartMate and Novacor were 0.84 and 0.80 and 0.72 and 0.56, respectively, following heart transplantation. Adjusting for patient demographics and co-morbidities, no statistical significant difference in one-year survival was observed between those who received HeartMate and Novacor (HR = 1.49, p = 0.127). At five years, however, the HeartMate group had higher survival than Novacor (HR = 1.53, p = 0.043). All-time posttransplant hospitalizations due to infection and rejection were similar between HeartMate and Novacor recipients after adjusting for patient case mix. Controlling for patient case mix, there was no survival difference at one year between those who received Novacor versus HeartMate LVAD. At five years, a Novacor bridge to transplant patient on average had statistically significantly lower survival than HeartMate recipients. No difference in infection and rejection were observed.
- 1 January 2009
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 87 (1) , 261-266
Survival of Primary and Repeat Lung Transplantation in the United States
- 1 January 2009
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 87 (1) , 261-266
Survival of Primary and Repeat Lung Transplantation in the United States
- 1 December 2008
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 27 (12) , 1348-1349
Pseudoaneurysm of Ascending Aorta After Biventricular Assist Device Support
- 1 December 2008
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 27 (12) , 1348-1349
Pseudoaneurysm of Ascending Aorta After Biventricular Assist Device Support
- 31 October 2008
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 27 (10) , 1122-1127
Repeat Heart–Lung Transplantation Outcome in the United States
- 31 October 2008
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 27 (10) , 1122-1127
Repeat Heart–Lung Transplantation Outcome in the United States
- 27 October 2008
- Published by Hindawi Limited in Journal of Cardiac Surgery
- Vol. 23 (6) , 688-690
Surgical Treatment of Subaortic Stenosis and Noncompaction of the Left Ventricle
Late presentation of noncompaction of the left ventricle is rare, especially in the adult congenital population. We describe successful surgical management of severe pulmonary hypertension related to severe left ventricular outflow tract narrowing in the context of noncompaction of the ventricle in a 46-year-old female.
- 27 October 2008
- Published by Hindawi Limited in Journal of Cardiac Surgery
- Vol. 23 (6) , 688-690
Surgical Treatment of Subaortic Stenosis and Noncompaction of the Left Ventricle
Late presentation of noncompaction of the left ventricle is rare, especially in the adult congenital population. We describe successful surgical management of severe pulmonary hypertension related to severe left ventricular outflow tract narrowing in the context of noncompaction of the ventricle in a 46-year-old female.
- 19 August 2008
- Published by Hindawi Limited in Journal of Cardiac Surgery
- Vol. 23 (5) , 552
Intra-Cardiac Thrombosis Following Aortic Valve Replacement
- 19 August 2008
- Published by Hindawi Limited in Journal of Cardiac Surgery
- Vol. 23 (5) , 552
Intra-Cardiac Thrombosis Following Aortic Valve Replacement
- 11 July 2008
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 136 (4) , 894-899
The influence of seasonal variation on cardiac surgery: A time-related clinical outcome predictor
- 11 July 2008
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 136 (4) , 894-899
The influence of seasonal variation on cardiac surgery: A time-related clinical outcome predictor
- 1 July 2008
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 86 (1) , 123-131
Impact of Cardiothoracic Resident Turnover on Mortality After Cardiac Surgery: A Dynamic Human Factor
- 1 July 2008
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 86 (1) , 123-131
Impact of Cardiothoracic Resident Turnover on Mortality After Cardiac Surgery: A Dynamic Human Factor
- Open Access
- 1 May 2008
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 33 (5) , 849-855
Does perioperative use of aprotinin reduce the rejection rate in heart transplant recipients??
Objective: Allograft rejection continues to be one of the most common causes of mortality after heart transplantation. We investigated if perioperative use of antifibrinolytics such as aprotinin and tranexamic acid can decrease the rate of rejection after heart transplant and their effect on transfusion. Methods: A retrospective analysis was conducted on the data from patients who received a first heart transplant at Papworth Hospital between 2000 and 2005. Transplant registry and audit data were used for the study. Rejection biopsy results and treatment were used to designate rejection episodes as mild (grades 1A, 1B or 2 untreated) or severe (grades 2 treated, grades 3 and 4). The relationship between antifibrinolytics and rejection episodes was assessed using univariate and multiple Poisson regression. Kaplan–Meier methods and Kruskal–Wallis tests, respectively, were used to analyse survival/time to first rejection and transfusion. Results: There were 225 patients who underwent a first heart transplant between January 2000 and December 2005. Of these, 101 patients (44.9%) had received aprotinin, 63 (28.0%) tranexamic acid, 2 (0.9%) both (aprotinin and tranexamic acid) and 59 (26.2%) no antifibrinolytics. There was no difference in time to first rejection by antifibrinolytic treatment (p = 0.20). There was no difference in the rate of treated rejection per 100 patient-days between aprotinin and tranexamic acid groups between 0 and 3 months post-transplant, (0.6 in both), but aprotinin had a small clinical effect when compared to no treatment (0.6 vs 0.8, p = 0.54). Between 4 and 6 months, the treated and severe rejection rates were lower in the patients receiving aprotinin as compared to those receiving tranexamic acid, but these differences again did not reach statistical significance (0.1 vs 0.3, p = 0.14, 0.2 vs 0.4, p = 0.18). Aprotinin was associated with higher postoperative blood loss and transfusion requirements in the subgroup of patients that had a ventricular assist device, prior sternotomy or anticoagulant therapy. Conclusions: The use of aprotinin in heart transplant surgery may be associated with a small decrease in the incidence of treated/severe rejection within 6 months of transplantation. The perioperative use of antifibrinolytics did not influence time to first rejection or reduce blood transfusion.
- 1 May 2008
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 33 (5) , 849-855
Open AccessDoes perioperative use of aprotinin reduce the rejection rate in heart transplant recipients??
Objective: Allograft rejection continues to be one of the most common causes of mortality after heart transplantation. We investigated if perioperative use of antifibrinolytics such as aprotinin and tranexamic acid can decrease the rate of rejection after heart transplant and their effect on transfusion. Methods: A retrospective analysis was conducted on the data from patients who received a first heart transplant at Papworth Hospital between 2000 and 2005. Transplant registry and audit data were used for the study. Rejection biopsy results and treatment were used to designate rejection episodes as mild (grades 1A, 1B or 2 untreated) or severe (grades 2 treated, grades 3 and 4). The relationship between antifibrinolytics and rejection episodes was assessed using univariate and multiple Poisson regression. Kaplan–Meier methods and Kruskal–Wallis tests, respectively, were used to analyse survival/time to first rejection and transfusion. Results: There were 225 patients who underwent a first heart transplant between January 2000 and December 2005. Of these, 101 patients (44.9%) had received aprotinin, 63 (28.0%) tranexamic acid, 2 (0.9%) both (aprotinin and tranexamic acid) and 59 (26.2%) no antifibrinolytics. There was no difference in time to first rejection by antifibrinolytic treatment (p = 0.20). There was no difference in the rate of treated rejection per 100 patient-days between aprotinin and tranexamic acid groups between 0 and 3 months post-transplant, (0.6 in both), but aprotinin had a small clinical effect when compared to no treatment (0.6 vs 0.8, p = 0.54). Between 4 and 6 months, the treated and severe rejection rates were lower in the patients receiving aprotinin as compared to those receiving tranexamic acid, but these differences again did not reach statistical significance (0.1 vs 0.3, p = 0.14, 0.2 vs 0.4, p = 0.18). Aprotinin was associated with higher postoperative blood loss and transfusion requirements in the subgroup of patients that had a ventricular assist device, prior sternotomy or anticoagulant therapy. Conclusions: The use of aprotinin in heart transplant surgery may be associated with a small decrease in the incidence of treated/severe rejection within 6 months of transplantation. The perioperative use of antifibrinolytics did not influence time to first rejection or reduce blood transfusion.